A case of ovarian carcinosarcoma with germline BRCA2 pathogenic variant.
BRCA
germline pathogenic variant
hereditary breast and ovarian cancer syndrome (HBOC)
ovarian carcinosarcoma
poly(adenosine diphosphate‐ribose) polymerase (PARP) inhibitor
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
10
05
2024
accepted:
14
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
Ovarian carcinosarcoma in hereditary breast and ovarian cancer syndrome is rare. A 43-year-old woman with a family history of prostate and uterine or ovarian cancer had an 8-cm mass in the right ovary. Although computed tomography suggested peritoneal dissemination to the Douglas pouch, she wanted to preserve her fertility; therefore, she underwent a right salpingo-oophorectomy. Histopathological diagnosis was carcinosarcoma consisting of high-grade serous carcinoma and sarcomatous components, including cartilage. Three weeks later, she underwent radical surgery. The disease was classified as advanced stage IIIB (FIGO 2014). A germline BRCA2 pathogenic variant was identified. After postoperative adjuvant chemotherapy, maintenance therapy with a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor was continued for 25 months without recurrence. A detailed examination of a mass in her left breast at her first visit revealed a ductal carcinoma in situ. PARP inhibitors may be effective as maintenance therapy for advanced ovarian carcinosarcoma with germline BRCA mutations.
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Japan Society of Obstetrics and Gynecology.
Références
Chen S, Parmigiani P. Meta‐analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–1333.
Brown E, Stewart M, Rye T, al‐Nafussi A, Williams ARW, Bradburn M, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004;100:2148–2153.
Kunkel J, Peng Y, Tao Y, Krigman H, Cao D. Presence of a sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mullerian tumors: a clinicopathologic study of 47 cases. Am J Surg Pathol. 2012;36:831–837.
Ko ML, Jeng CJ, Huang SH, Shen J, Tzeng CR, Chen SC. Primary peritoneal carcinosarcoma (malignant mixed Mullerian tumor): report of a case with five‐year disease free survival after surgery and chemoradiation and a review of literature. Acta Oncol. 2005;44:756–760.
Carnevali IW, Cimetti L, Sahnane N, Libera L, Cavallero A, Formenti G, et al. Two cases of carcinosarcomas of the ovary involved in hereditary cancer syndromes. Int J Gynecol Pathol. 2017;36:64–70.
Magalhães D, Bartosch C, Abreu MH. Do not forget poly (adenosine diphosphate‐ribose) polymetase inhibitors in ovarian carcinosarcoma. Cureus. 2022;14:e26662.
Saito A, Yamashita E, Sakurai U, Hirasawa A, Tanioka M, Tamura K, et al. A case of ovarian carcinosarcoma with a germline pathogenic variant of BRCA2 involving a perforated appendix with an abscess. J Obstet Gynaecol Res. 2023;49:2553–2557.
St Laurent JD, Abel MK, Liu J, Quade BJ, Davis MR. Successful treatment of stage IVB ovarian carcinosarcoma with PARP inhibitor: a case report. Gynecol Oncol Rep. 2024;51:101322.
Mendes Gomes LB, Lazari Sandoval R, Bragança Xavier C, Strava Correa T, Koga Matuda RM, Silva de Souza Z, et al. Primary peritoneal carcinosarcoma in a breast cancer patient harboring a germline BRCA2 pathogenic variant: case report. Case Rep Oncol. 2024;17:1–9.
See SHC, Behdad A, Maniar KP, Blanco LZ Jr. Ovarian carcinosarcoma and concurrent serous tubal intraepithelial carcinoma with next‐generation sequencing suggesting an origin from the fallopian tube. Int J Surg Pathol. 2019;27:574–579.
Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, Takeshima N, et al. The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: characterizing the cross‐sectional approach to ovarian cancer genetic testing of BRCA (CHARLOTTE). Int J Gynecol Cancer. 2019;29:1043–1049.
Sia TY, Gordhandas SB, Birsoy O, Kemel Y, Maio A, Salo‐Mullen E, et al. Germline drivers of gynecologic carcinosarcomas. Gynecol Oncol. 2023;174:34–41.
Schouten PC, Schmidt S, Becker K, Thiele H, Nürnberg P, Richters L, et al. Olaparib addition to maintenance bevacizumab therapy in ovarian carcinoma with BRCA‐like genomic aberrations. JAMA Netw Open. 2024;7:e245552.
Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20:764–775.
National Comprehensive Cancer Network, Inc. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. V3. 2024. [Cited 10 August 2024]. Available from NCCN.org